Springer Nature AG & Co. KGaA
SPG
ISIN DE000SPG1003 / Valor 41578404
Springer Nature AG & Co. KGaA
UMushroom community rating:
About company
Springer Nature AG & Co. KGaA is a prominent global academic publishing company that specializes in providing high-quality content and services across various scientific, technical, and medical fields. Formed through the merger of Springer Science+Business Media and Macmillan Science and Education, the company is known for its extensive portfolio of journals, books, and digital resources that support researchers, educators, and professionals worldwide. Springer Nature plays a significant role in advancing discovery by offering innovative solutions and platforms that facilitate the dissemination of knowledge. The company is structured to cater to diverse research needs, with dedicated divisions focusing on research publishing, educational resources, and professional development. Through its commitment to fostering open access and supporting the global research community, Springer Nature continues to be a key player in the academic publishing industry.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (03.04.2026):
Springer Nature AG & Co. KGaA — Q3 2025 (first nine months of 2025): The group reported strong nine‑month results with revenue of €1,428.7m (underlying +5.9%) and adjusted operating profit (AOP) of €408.3m (underlying +9.9%). Research outperformed the market (Research revenue €1,112.6m, underlying +7.0), Free Cash Flow rose to €174.5m, net leverage fell to 1.9x, and full‑year 2025 guidance was reiterated (revenue €1,930–1,960m; AOP €540–560m).
Top‑line and profitability
Nine‑month revenue €1,428.7m (+5.9% underlying) and AOP €408.3m (+9.9% underlying), with margin improvement driven by product mix, operating leverage and efficiency measures.
Research segment performance
Research (largest segment) revenue €1,112.6m (underlying +7.0%). Journals grew above the market, Full Open Access (FOA) particularly strong — published articles +>10% overall and +>25% in FOA. Research AOP €351.5m (underlying +8.2%), outpacing revenue growth.
Other segments — Health & Education
Health: revenue €135.9m (underlying +4.3%), AOP €25.7m (underlying +22.3%). Education: revenue €181.1m (underlying +0.7%; reported -7.0% due to FX/hyperinflation), AOP €31.0m (underlying +23.0%) aided by efficiency and product‑mix changes.
Cash, leverage and credit
Free cash flow up €102.7m to €174.5m, aided by better operations and lower interest; net debt/adjusted EBITDA 1.9x (target range 1.5–2.0x). Fitch assigned a BBB‑ long‑term issuer default rating in October 2025.
Open access, contracts and product investment
Springer Nature signed 18 transformative agreements in the first nine months (84 total to date) to accelerate open access. Continued investments in AI and product development — Nature Research Assistant now used by >8,000 beta users.
Guidance and FX sensitivity
Full‑year 2025 guidance reaffirmed: revenue €1,930–1,960m and AOP €540–560m (at constant 2025 FX). Report notes USD weakness could reduce FY revenue by ~€11m and AOP by ~€12m (assuming EUR/USD 1.148 YTG); other non‑USD FX ~€‑9m revenue / ~€+3m AOP at current rates.
Management view
Management cites continued Research momentum, efficiency gains and AI/tech innovation as the basis for confidence in meeting 2025 guidance and positioning for 2026 growth.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
4532 M
Market cap (USD)
35,565
Daily traded volume (Shares)
28.3 / 27
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
